880 related articles for article (PubMed ID: 15296838)
21. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Moore AE; Cicchetti F; Hennen J; Isacson O
Exp Neurol; 2001 Dec; 172(2):363-76. PubMed ID: 11716560
[TBL] [Abstract][Full Text] [Related]
22. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
Henderson JM; Stanic D; Tomas D; Patch J; Horne MK; Bourke D; Finkelstein DI
Behav Brain Res; 2005 May; 160(2):267-76. PubMed ID: 15863223
[TBL] [Abstract][Full Text] [Related]
23. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats.
Sarre S; Yuan H; Jonkers N; Van Hemelrijck A; Ebinger G; Michotte Y
J Neurochem; 2004 Jul; 90(1):29-39. PubMed ID: 15198664
[TBL] [Abstract][Full Text] [Related]
24. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Iancu R; Mohapel P; Brundin P; Paul G
Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
[TBL] [Abstract][Full Text] [Related]
25. Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease.
Cass WA; Peters LE; Smith MP
Brain Res; 2005 Feb; 1034(1-2):153-61. PubMed ID: 15713267
[TBL] [Abstract][Full Text] [Related]
26. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
27. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Olds ME; Jacques DB; Kopyov O
Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
[TBL] [Abstract][Full Text] [Related]
28. Effects of zona incerta lesions on striatal neurochemistry and behavioral asymmetry in 6-hydroxydopamine-lesioned rats.
Walker RH; Davies G; Koch RJ; Haack AK; Moore C; Meshul CK
J Neurosci Res; 2010 Oct; 88(13):2964-75. PubMed ID: 20544826
[TBL] [Abstract][Full Text] [Related]
29. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
Georgievska B; Carlsson T; Lacar B; Winkler C; Kirik D
Eur J Neurosci; 2004 Dec; 20(11):3121-30. PubMed ID: 15579166
[TBL] [Abstract][Full Text] [Related]
30. Neurotoxic action of 6-hydroxydopamine on the nigrostriatal dopaminergic pathway in rats sensitized with D-amphetamine.
Nowak P; Kostrzewa RM; Kwieciński A; Bortel A; Labus Ł; Brus R
J Physiol Pharmacol; 2005 Jun; 56(2):325-33. PubMed ID: 15985712
[TBL] [Abstract][Full Text] [Related]
31. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
32. A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Thomas J; Wang J; Takubo H; Sheng J; de Jesus S; Bankiewicz KS
Exp Neurol; 1994 Apr; 126(2):159-67. PubMed ID: 7925817
[TBL] [Abstract][Full Text] [Related]
33. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
[TBL] [Abstract][Full Text] [Related]
34. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
35. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
Gomes MZ; Raisman-Vozari R; Del Bel EA
Brain Res; 2008 Apr; 1203():160-9. PubMed ID: 18313645
[TBL] [Abstract][Full Text] [Related]
36. Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
Metz GA; Piecharka DM; Kleim JA; Whishaw IQ
Brain Res; 2004 Nov; 1026(1):126-35. PubMed ID: 15476704
[TBL] [Abstract][Full Text] [Related]
37. Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Fornaguera J; Schwarting RK; Boix F; Huston JP
Synapse; 1993 Feb; 13(2):179-85. PubMed ID: 7680495
[TBL] [Abstract][Full Text] [Related]
38. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
Kirik D; Rosenblad C; Björklund A
Exp Neurol; 1998 Aug; 152(2):259-77. PubMed ID: 9710526
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
40. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
